DiagnaMed Enters into License Agreement with University of Miami

Wednesday, February 22, 2023

DiagnaMed Holdings announce that it has entered into a licence agreement with the University of Miami (“UM”) for the development and commercialisation of intellectual property of a novel brain health platform for the evaluation, diagnosis and monitoring of brain health, such as Alzheimer's disease and related dementias (“ADRD”).

With the integration of UM’s brain health platform, CERVAI™ will add the ability to delay or prevent the onset of cognitive decline, thereby improving the quality of life for patients and caregivers, providing a diagnostic application which comprehensively and objectively produce a risk assessment to inform a tailored intervention and enhance enrolment in prevention studies and clinical trials of disease-modifying therapies.

The UM brain health platform features various novel brain function assessments and tools to evaluate overall brain health, ADRD risk factors, cognitive performance, and evidence of risk of further decline and future impairment, which are validated against clinical gold standards of normal and impaired cognitive function. The UM brain health platform will intake the inputs of these assessments and output a patient risk score, from which tailored interventions, including medications and clinical trial enrolment, are implemented in at-risk individuals to decrease the development or progression of cognitive decline.